The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial

Seyyedebrahimi, ShadiSadat; Khodabandehloo, Hadi; Esfahani, Ensieh Nasli; Meshkani, Reza

doi:10.1007/s00592-017-1098-3

Cited by 133 publications

(105 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several trials have aimed to investigate the antiobesity effects of resveratrol in human. Contrary to our findings, some trials revealed significant effects of resveratrol supplementation on anthropometric measures in patients with T2DM (Imamura et al, 2017;Kumar & Joghee, 2013;Seyyedebrahimi, Khodabandehloo, Esfahani, & Meshkani, 2018). However, one study reached null results (Bo et al, 2016).…”

Section: Discussioncontrasting

confidence: 99%

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

Abdollahi

Salehi‐Abargouei

Toupchian

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

The aim of the present randomized controlled trial was to evaluate the effect of a micronized resveratrol supplement on glycemic status, lipid profile, and body composition in patients with type 2 diabetes mellitus (T2DM). A total of 71 overweight patients with T2DM (body mass index ranged 25–30) were randomly assigned to receive 1000 mg/day trans‐resveratrol or placebo (methyl cellulose) for 8 weeks. Anthropometric indices and biochemical indices including lipid and glycemic profile were measured before and after the intervention. In adjusted model (age, sex, and baseline body mass index), resveratrol decreased fasting blood sugar (−7.97±13.6 mg/dL, p=0.05) and increased high density lipoprotein (3.62±8.75 mg/dL, p=0.01) levels compared with placebo. Moreover, the mean difference in insulin levels reached significance (−0.97±1.91, μIU/mL, p= 0.02). However, no significant differences were observed for anthropometric measures. It was found that 8‐week resveratrol supplementation produced useful effects on some cardio‐metabolic parameters in patients with T2DM. More studies are needed to confirm these findings.

show abstract

Section: Discussioncontrasting

confidence: 99%

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

Abdollahi

Salehi‐Abargouei

Toupchian

et al. 2019

Phytotherapy Research

View full text Add to dashboard Cite

show abstract

“…The results of two studies on mice indicated that oral administration of 20 mg/kg/d of RSV for 2 weeks downregulated the expression of RAGE . However, two human studies showed inconsistent results for the effects of RSV on glycation reactions and expression of RAGE . Roggerio et al demonstrated that receiving 500 mg/day of RSV for 30 days decreased the gene expression but not the serum concentration of RAGE .…”

Section: Resultsmentioning

confidence: 99%

“…Roggerio et al demonstrated that receiving 500 mg/day of RSV for 30 days decreased the gene expression but not the serum concentration of RAGE . Seyyedebrahimi et al also found that oral supplementation of 800 mg/day RSV for 2 months considerably decreased plasma protein carbonyl content in the patients with DM while the expression of RAGE and Nrf 2 have not been affected …”

Section: Resultsmentioning

confidence: 99%

The impact of resveratrol on toxicity and related complications of advanced glycation end products: A systematic review

et al. 2019

View full text Add to dashboard Cite

Accumulation of advanced glycation end products (AGEs) promotes the generation of free radicals, which leads to chronic oxidative stress predisposing to chronic oxidative stress, inflammation, and related diseases. This systematic review aimed to determine the effect of resveratrol (RSV) on AGE‐induced toxicity and its deleterious consequences. A comprehensive search was performed through literature were published until December 2018 using relevant keywords. The databases that were used for the search were PubMed, Scopus, Embase, ProQuest, and Google Scholar. A total of 29 eligible studies were found and included in the review for the analysis. Except one, all studies showed suppressing effects for RSV on the production of AGEs or receptor for advanced glycation end products (RAGE) and its detrimental consequences including oxidative stress, inflammatory response, cellular immune reactions, insulin response, and atherosclerosis. RSV exerts its effects through influencing RAGE, nuclear factor kappa B (NF‐κB), peroxisome proliferator‐activated receptor (PPAR) γ, and transforming growth factor (TGF)‐β activities. This review suggests that RSV has got potential to decrease AGEs toxicity and inhibit the AGE‐induced complications. More clinical trials are suggested to evaluate the beneficial effect of RSV on AGEs in chronic metabolic diseases.

show abstract

“…To avoid cellular damage by ROS, hepatocytes neutralize the harmful effects of ROS by activating the antioxidant enzymes such as heme oxygenase 1 ( HO1 ), NAD(P)H:Quinone Oxidoreductase 1 ( NQO1 ), and manganese superoxide dismutase ( Mn‐SOD ). Importantly, many of these antioxidant enzymes are encoded by genes that are regulated by transcription factor nuclear factor‐erythroid 2‐related factor 2 (Nrf2) . In this regard, it has been demonstrated that Nrf2 protects hepatocytes against oxidative damage through its important function in the prevention of oxidative stress.…”

Section: Introductionmentioning

confidence: 99%

“…Importantly, many of these antioxidant enzymes are encoded by genes that are regulated by transcription factor nuclear factor-erythroid 2-related factor 2 (Nrf2). 9,10 In this regard, it has been demonstrated that Nrf2 protects hepatocytes against oxidative damage through its important function in the prevention of oxidative stress. Besides the activation of the genes involved in the elimination of ROS derived from lipid peroxidation, the protective role of Nrf2 in NAFLD is also mediated through negative regulation of genes that promote hepatic lipid deposition.…”

Section: Introductionmentioning

confidence: 99%

Inhibiting miR‐27a and miR‐142‐5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary The gene Nrf2 (nuclear factor‐erythroid 2‐related factor 2) is the most important regulator of the cellular antioxidant system and its dysregulation has a role in the etiology of nonalcoholic fatty liver disease (NAFLD). The aim of this study was to investigate the association between Nrf2 targeted miRNAs (miR‐27a, miR‐142‐5p, miR‐153, and miR‐128) with lipid accumulation in vitro and in vivo models of NAFLD. We used two in vivo and in vitro models of NAFLD. The expression of the genes and miRNAs was assessed by real‐time PCR and the protein level was evaluated using western blot. To investigate the potential role of miRNAs in NAFLD, the inhibitors or mimics of the miR‐27a and miR‐142‐5p were transfected into HepG2 cells. The mRNA and protein levels of Nrf2 were significantly decreased in the liver of high fat diet‐fed mice as well as in HepG2 cells treated with high glucose (HG). Reduced expression of Nrf2 was associated with increased expression levels of miR‐27a and miR‐142‐5p in both models of NAFLD. HG‐induced triglyceride accumulation was attenuated by inhibition of miR‐27a or miR‐142‐5p in HepG2 cells. Overexpression of miR‐27a or miR‐142‐5p suppressed the expression of Nrf2 and its downstream antioxidant genes and increased production of reactive oxygen species, whereas inhibition of miR‐27a or miR‐142‐5p reversed these effects. In conclusion, the data of this study may suggest that miR‐27a and miR‐142‐5p are increased in NAFLD, where they suppress Nrf2 expression and contribute to the accumulation of lipids in the hepatocytes.

show abstract

The effects of resveratrol on markers of oxidative stress in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled clinical trial

Abstract: Our study demonstrated that 8 weeks of supplementation with 800 mg/day resveratrol has an antioxidant effect in the blood and PBMCs of patients with T2D. Clinical Trial Registry number and website IRCT registration number: IRCT2015072523336N1 and http://en.search.irct.ir/view/24752 .

Cited by 133 publications

References 48 publications

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

The Effect of Resveratrol Supplementation on Cardio‐Metabolic Risk Factors in Patients with Type 2 Diabetes: A Randomized, Double‐Blind Controlled Trial

The impact of resveratrol on toxicity and related complications of advanced glycation end products: A systematic review

Inhibiting miR‐27a and miR‐142‐5p attenuate nonalcoholic fatty liver disease by regulating Nrf2 signaling pathway

Contact Info

Product

Resources

About